Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod in CIDP
NCT01625182Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2012
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of fingolimod in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), sponsored by Novartis. Started Dec 2012; status: completed.
02
Drugs
fingolimod
03
Conditions
chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
Beyond the preview
Go deeper on NCT01625182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01625182.